Anticancer Effects of Cirsimaritin in A375 and MeWo Cutaneous Melanoma Cells Are Partially Blocked by a G Protein-Coupled Estrogen Receptor Antagonist
This study demonstrates that the flavonoid cirsimaritin exerts antitumor effects on cutaneous melanoma cells by inhibiting viability, migration, and cell cycle progression while inducing apoptosis, with these actions being partially mediated through the G protein-coupled estrogen receptor (GPER) signaling pathway.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Skin cancer takes many forms, but the most dangerous is melanoma, a disease that begins in the pigment-producing cells of the skin. While sunlight is the primary trigger, scientists have long suspected that the body's own chemical messengers, specifically hormones like estrogen, play a hidden role in how these cancer cells grow and spread. For decades, researchers focused on the classic estrogen receptors found inside the nucleus of a cell, but a newer discovery has shifted attention to a different receptor called GPER. This receptor sits on the surface of cells and acts like a rapid-response antenna, triggering immediate signals that can tell a cell to divide, survive, or move. Understanding how to turn this antenna on or off could open a new door for treating aggressive cancers that are difficult to stop with current therapies.
In a recent study, a team of researchers from Jordan explored whether a natural plant compound called cirsimaritin could harness this mechanism to fight melanoma. Cirsimaritin is a substance found in various medicinal plants, known for its ability to fight inflammation and bacteria, but its specific effects on skin cancer were not well understood. The scientists decided to test this compound on two distinct types of human melanoma cells grown in a laboratory. One type, known as A375, carries a specific genetic mutation common in many skin cancers, while the other, MeWo, does not. By using these two different models, the researchers could see if the treatment worked regardless of the cancer's genetic makeup.
The researchers began by exposing the cancer cells to increasing amounts of cirsimaritin and watched what happened over several days. They found that the compound acted as a powerful brake on the cancer. As the dose increased, the cells stopped growing and began to die. In the A375 cells, the treatment reduced the number of living cells to about 41 percent of the original amount, while in the MeWo cells, it was even more effective, dropping survival to roughly 26 percent. The cells did not just stop dividing; they also lost their ability to move, a critical trait that allows cancer to spread to other parts of the body. Under the microscope, the treated cells looked different, shrinking and pulling away from their neighbors, signs that they were under severe stress and preparing to self-destruct.
To understand exactly how cirsimaritin was causing this damage, the team looked inside the cells to see which internal signals were firing. They discovered that the compound triggered a chain reaction that forced the cancer cells into a state of programmed death, known as apoptosis. In the A375 cells, the treatment pushed the death rate up significantly, and in the MeWo cells, it was even higher. Furthermore, the compound disrupted the cell cycle, which is the schedule a cell follows to copy itself and divide. The treatment caused the cells to get stuck in the middle of this process, unable to finish their work and multiply. This suggests that cirsimaritin does not just kill the cells randomly but interferes with the fundamental machinery that keeps them alive.
A crucial part of the study was determining whether these effects were happening because the compound was interacting with the GPER antenna on the cell surface. To test this, the scientists used a special blocker, a substance designed to shut down GPER specifically. When they added this blocker before introducing cirsimaritin, the cancer-fighting effects of the plant compound were significantly weakened. The cells were able to survive and move much better than they did when treated with cirsimaritin alone. This result strongly suggests that cirsimaritin works by activating the GPER receptor, which then sends signals to the cell to stop growing and start dying. The researchers also observed that the compound changed the levels of key proteins inside the cell, such as c-Myc and ERK, which are known to control cell growth and survival. Notably, contrary to what might be expected, the treatment actually increased the expression of c-Myc, a finding the researchers attributed to a complex cellular response where this protein may help drive the cells toward death rather than survival. This rewiring of the internal signaling network confirms that the compound is actively disrupting the cancer's communication lines.
The study also revealed some interesting differences between the two types of cancer cells. While both responded well to the treatment, the way their internal proteins reacted varied slightly. In one cell line, the treatment reduced a specific survival signal, while in the other, it increased a different growth signal before ultimately causing the cell to die. This complexity highlights that while the overall result was the same—slowing down the cancer—the path to get there was not identical for every cell type. Despite these subtle variations, the core finding remained consistent: cirsimaritin effectively targets the cancer cells, and its power relies heavily on the presence of the GPER receptor.
This research provides a clear picture of how a natural compound can be repurposed to fight a deadly disease by targeting a specific receptor on the cell surface. The study shows that cirsimaritin is not just a general poison to cells but a precise agent that disrupts the communication lines melanoma cells use to survive and spread. While the work was done in a laboratory setting and not yet in living patients, the results offer a promising new direction. They suggest that targeting the GPER receptor with natural substances could be a viable strategy for developing new treatments for cutaneous melanoma, potentially offering hope for patients whose cancers are driven by these specific signaling pathways.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.